Oncolix is currently recruiting patients for the continuation of their Phase I. The issue with Oncolix has not been a shortage of patients, it has been a shortage of their drug, Prolanta.
They had enough patients ready to go for Phase I back in 2016, but were only able to bring 3 of those patients to completion. The reason they had to stop was due to the shortage of Prolanta as mentioned above. This information can be verified by calling Lisa Johnson, which I've done, who is listed on the the trial page information that you copied and pasted.
Why was there a shortage of the drug? One can only assume they had their financing sources fall by the wayside. Now that Oncolix has gone public they can fund their operation via the sale of securities.
As the company has stated and Lisa Johnson has verified, they did start phase I in 2016 and were able to compete 3 patients in that initial run. I emailed the CEO, Michael Redman, and asked him why the trial page had been updated in April 2017, but still remained in a recruiting status, and this was his response:
"Normally you do not update the site until you have audited data. Much of the biomarker work will be performed once we have dosed all the patients. Remember, the primary endpoint for a Phase 1 study is safety but it is always good to observe evidence of efficacy. So far, no adverse events due to the drug have been reported."
AI
